-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Serum testosterone concentration decreased with age, while serum hormone binding globulin (SHBG) concentration increased.
recently, a study published in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, was designed to analyze the relationship between baseline serum testosterone, SHBG concentrations, and calculated free testosterone (cFT) values and male total cause and specific emoticon mortality.
study looked at prospective cohort studies of men aged 40-69 in the community for 11 years.
the study were total cause, atherosclerosis cardiovascular disease (CVD), and cancer-related mortality.
researchers performed Cox-proportional risk regression and adjusted age, waist circumference, medical condition, and other covariates.
testosterone contains SHBG and vice versa.
in a full case analysis of 149,436 men, there were 1,053 deaths (1925 CVD and 4927 cancer-related deaths), and the total cause of lower testosterone levels in men (minimum and maximum five-digit, Q1 and Q5, fully adjusted risk ratio was 1.14,95% The higher mortality rates were associated with higher mortality rates in the confidence interval of 1.06-1.22, the overall trend of P.lt;0.001) and cancer (HR.1.20, 95% CI, 1.09-1.33, P.lt;0.001), independent of CVD deaths.
similar results were observed for cfT.
SHBG lower male all-cause (Q1 vs. Q5, HR=0.68,95% CI=0.63-0.73, P<0.001), CVD (HR=0.70,95 The mortality rates were lower for %CI.0.59-0.83, P.lt;0.001) and cancer (HR=0.80, 95% CI=0.72-0.89, P<0.001).
the multi-calculation data set (N-208425, 15914 deaths, 3,128 CVD deaths and 7,468 cancer-related deaths) and the analysis excluded deaths in the first two years (9261, 1734 and 4534 events) to get similar results.
result, lower serum testosterone was associated with higher all-cause and cancer mortality rates in middle-aged and older men, but not CVD deaths.
SHBG was associated with lower all-cause, CVD-related and cancer-related mortality.
.